Clinical Trials
| ACTIVE CLINICAL TRIALS | ||
|---|---|---|
| Study Name | PI / Sub-I | |
| A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| A Phase 2/3, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of mitapivat versus placebo in subjects with sickle cell disease. | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| A multicenter trial evaluating the efficacy and safety of oral decitabine-tetrahydro uridine (NDec) in patients with sickle cell disease | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of T-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| Sickle Cell Disease and Cardiovascular Risk – Red cell Exchange Trial (SCD-CARRE) | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD) | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|
| A phase III, Multicenter, Randomized, Placebo Controlled, Doubleblind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises | PI: Modupe Idowu, MD Sub-I: Oluwatosin Sule, NP |
|